Brief: Active Biotech partners with NeoTX for commercialization of ANYARA
26/10/2016 07:31
Oct 26 (Reuters) - Active Biotech Ab ACTI.ST
* Reg-Active Biotech and NeoTX enter into a partnership for
the development and commercialization of ANYARA for
immuno-oncology
* Under the terms of the agreement, Active Biotech grants
NeoTX exclusive rights to develop and commercialize ANYARA
worldwide in cancer indications
* The total deal value amounts to $71 million and is
contingent upon achievement of clinical, regulatory and
commercial milestones whereof Active Biotech will
receive $250 000 as an initial payment upon signing
* Says in addition, NeoTX will pay Active Biotech
progressive, double-digit royalties on its net sales
Source text for Eikon: ID:nGNE15y176
Further company coverage: ACTI.ST
(Stockholm Newsroom)
((stockholm.newsroom@thomsonreuters.com; +46 (0)8-700 10 10;))